2026
2026
Ethyreal Bio Achieves Proof of Mechanism in First-in-Human Study of ETHY-001 and Initiates First Patient Cohorts to Advance Development in Thyroid Eye Disease (TED) and Graves’ Disease (GD)
CAMBRIDGE, Mass., October 19, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology compan...Ethyreal Bio Achieves Proof of Mechanism in First-in-Human Study of ETHY-001 and Initiates First Patient Cohorts to Advance Development in Thyroid Eye Disease (TED) and Graves’ Disease (GD)
CAMBRIDGE, Mass., October 19, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology compan...October 19, 2026 • Cambridge, MA
October 19, 2026 • Cambridge, MA
2026
2026
Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED
CAMBRIDGE, Mass., June 15, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED
CAMBRIDGE, Mass., June 15, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...June 15, 2026 • Cambridge, MA
June 15, 2026 • Cambridge, MA
2026
2026
Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease
CAMBRIDGE, Mass., June 10, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease
CAMBRIDGE, Mass., June 10, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...June 10, 2026 • Cambridge, MA
June 10, 2026 • Cambridge, MA
2026
2026
Ethyreal Bio Achieves Proof of Mechanism in First-in-Human Study of ETHY-001 and Initiates First Patient Cohorts to Advance Development in Thyroid Eye Disease (TED) and Graves’ Disease (GD)
CAMBRIDGE, Mass., October 19, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology compan...Ethyreal Bio Achieves Proof of Mechanism in First-in-Human Study of ETHY-001 and Initiates First Patient Cohorts to Advance Development in Thyroid Eye Disease (TED) and Graves’ Disease (GD)
CAMBRIDGE, Mass., October 19, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology compan...October 19, 2026 • Cambridge, MA
October 19, 2026 • Cambridge, MA
2026
2026
Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED
CAMBRIDGE, Mass., June 15, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...Ethyreal Bio Presents First Preclinical Data on ETHY-001 at ENDO 2026, Demonstrating Complete Blockade of Autoantibody Activation of TSHR and Differentiated Activity in TED
CAMBRIDGE, Mass., June 15, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...June 15, 2026 • Cambridge, MA
June 15, 2026 • Cambridge, MA
2026
2026
Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease
CAMBRIDGE, Mass., June 10, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease
CAMBRIDGE, Mass., June 10, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...June 10, 2026 • Cambridge, MA
June 10, 2026 • Cambridge, MA
